01.06.2013 Views

HEARTLINE HSM Genoa Cardiology Meeting - Aristea

HEARTLINE HSM Genoa Cardiology Meeting - Aristea

HEARTLINE HSM Genoa Cardiology Meeting - Aristea

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

11<br />

Primary Safety Endpoint included:<br />

• Device embolization requiring retrieval;<br />

• Pericardial effusion requiring intervention;<br />

• Cranial bleeds and gastrointestinal bleeds;<br />

• Any bleed that requires ≥ 2uPRBC;<br />

Eighty-seven percent of implanted subjects were able to cease warfarin at days and the<br />

rate further increased at later time points; reasons for remaining on warfarin therapy after<br />

-days were observation of ow in the LAA (n = 0), physician order (n = 1 ), other<br />

reasons (n = 9).<br />

As far as safety endpoints are concerned events in device group were classied as<br />

ischemic stroke: they were all periprocedural and extended hospitalization by 7 days; three<br />

events were related to air embolism; one hemorrhagic stroke in device group vs 6 in control<br />

group were adjudicated. By note, device events occurred 1 days post implant while patient<br />

was on warfarin and /6 stroke events in control group patients resulted in death.<br />

In conclusion, in AF patients who were candidates for warfarin therapy, device closure of<br />

the LAA using the Watchman device (Atritech, Plymouth, MN) was associated with a<br />

reduction in hemorrhagic stroke risk vs warfarin, and all-cause stroke and all-cause<br />

mortality outcomes were noninferior to warfarin. 10<br />

Safety events, particularly pericardial effusion, were more common in the device group, but<br />

these have decreased over time with procedural modications and enhanced training, the<br />

researchers noted.<br />

Indications<br />

Currently, when to close LAA?<br />

Patients with:<br />

• Permanent atrial brillation<br />

• High risk of stroke<br />

And with:<br />

• Contraindication to warfarin<br />

• High risk of bleeding with OAC<br />

• Difcult to maintain INR within the therapeutic range<br />

• Poor compliance<br />

• Difculty to manage the patient because of logistic problems<br />

AMPLATZER ® Cardiac Plug (AGA Medical Corporation)<br />

The AMPLATZER Cardiac Plug (ACP; Figure 2) is a transcatheter self-expanding device<br />

constructed from a nitinol mesh and polyester patch, ACP consists of a lobe and a disc<br />

connected by a central waist.<br />

The ACP is available in 8 sizes: 16, 18, 20, 22, 2 , 26, 28, and 0 mm.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!